Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Prolong Pharmaceuticals (South Plainfield, NJ) a near clinical-stage biopharmaceuticals company focused sickle cell anemia, stroke and diabetic induced ischemia, closed a $30M Series C financing. Participants were not identified.

Aires Pharmaceuticals (San Diego, CA) a clinical-stage pharmaceutical company focused on small molecule combination therapy for the treatment of pulmonary arterial hypertension, closed a $20M Series B financing. Participants include MPM Capital and ProQuest Investments.

Capricor (Los Angeles, CA) a development-stage regenerative medicine company focused on stem cell therapies for treatment of cardiac disease, closed a $2M Series A financing. Participants include Broadview Ventures.

Cerenis Therapeutics (France) a clinical-stage biopharmaceutical company focused on dyslipidemia and aortic valve stenosis, closed a $13.6M Series C bring the total round to approximately $68.3M. Participants include IXO Private Equity.

Cardioxyl Pharmaceuticals (Chapel Hill, NC) a clinical-stage small molecule company focused on acute decompensated heart failure, closed a $15M Series C financing. Participants include Aurora Funds and New Enterprise Associates.

Cerenis Therapeutics (France), a clinical-stage biopharmaceutical company focused on the regression of atherosclerotic plaque and the enhancement of HDL function, closed a $40M Series C financing. Participants include Fund for Strategic Investment, Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.

InVasc Therapeutics (Tucker, GA) a clinical-stage biopharmaceutical company focused on the cardiometabloic diseases chronic kidney disease and atherosclerosis, closed a $3.1M Series A financing. Participants include Trois I Investments Industriels Internationaux.

Relypsa (Santa Clara, CA) a clinical-stage developer of a therapeutic for hyperkalemia in congestive heart failure patients, closed a $70M Series B financing. Participants include 5AM Ventures, New Leaf Partners, Delphi Ventures and OrbiMed Advisors.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on end stage renal disease, congestive heart failure, chronic kidney disease, and hypertension, closed a $21M Series B financing. Participants include AgeChem, CMEA Capital, ARCH Venture Partners, Sofinnova Ventures and Dow Venture Capital.

Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.

Bind Biosciences (Cambridge, MA) a preclinical-stage nanoparticle platform company focused on increased efficacy and reduced toxicity of currently marketed drugs, closed a $12.4M Series C financing. Participants include Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision.

FoldRx Pharmaceuticals (Cambridge) a clinical-stage small molecule company focused on protein misfolding and aggregation in transthyretin amyloid polyneuropathy and other neurodegenerative and cardiovascular diseases, closed a $29M Series C financing. Participants include Novo Ventures, Morgenthaler Ventures, HealthCare Ventures, Fidelity Biosciences, TPG Biotech, Alta Partners and Novartis Venture Funds.

NormOxys (Wellesley, MA) a clinical-stage small molecule company focused on allosteric effectors of hemoglobin for heart failure and various cancers, closed a $17.5M Series B financing. Participants include Care Capital and Index Ventures.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...